PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine whether monotherapy treatment with
phosphodiesterase-4 (PDE-4) inhibitor roflumilast is more effective than treatment with
glucagon-like protein 1 (GLP-1) liraglutide or treatment with metformin as monotherapy in the
treatment of obese women with polycystic ovary syndrome (PCOS) regarding weight reduction who
have not been treated before. The investigators anticipated greater changes in body weight in
patients on roflumilast treatment than in liraglutide or metformin.